Xencor appoints board member
This article was originally published in Scrip
Xencor, a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, has named Dr Bruce Montgomery a member of its board of directors. Currently, Dr Montgomery serves as CEO of Cardeas Pharma. Prior to Cardeas, he was senior vice-president of Gilead Sciences and was founder and CEO of Corus Pharma, until it was acquired by Gilead in 2006.
You may also be interested in...
A complete response letter from the FDA in June knocked Intercept’s stock price down to 2014 levels, but perhaps the regulator is sending wider messages about NASH.
A selection of features you might have missed from the first six months of 2020, covering key topics from COVID-19 strategies in medtech to an analysis of pipeline focus areas across the pharma sector. Click on each section to get the full story behind the data.
The two-part vaccine becomes the second against Ebola to get approval. Janssen is now collaborating with the World Health Organization on vaccine pre-qualification to get it to people in need.